As of close of business last night, Esperion Therapeutics Inc.’s stock clocked out at $2.07, up 0.98% from its previous closing price of $2.05. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 10729140 shares were traded.
Ratios:
To gain a deeper understanding of ESPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.29.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 20 ’23 when Warren Eric sold 742 shares for $1.25 per share. The transaction valued at 924 led to the insider holds 68,318 shares of the business.
Warren Eric sold 243 shares of ESPR for $344 on Aug 18 ’23. The Chief Commercial Officer now owns 69,060 shares after completing the transaction at $1.41 per share. On Jul 19 ’23, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 106 shares for $1.58 each. As a result, the insider received 168 and left with 69,303 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 383.98M and an Enterprise Value of 567.91M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.03. Its current Enterprise Value per Revenue stands at 4.88 whereas that against EBITDA is -3.78.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $4.05, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 2.4334, while the 200-Day Moving Average is calculated to be 1.6482.
Shares Statistics:
It appears that ESPR traded 6.00M shares on average per day over the past three months and 3.96M shares per day over the past ten days. A total of 170.42M shares are outstanding, with a floating share count of 169.51M. Insiders hold about 0.53% of the company’s shares, while institutions hold 48.10% stake in the company. Shares short for ESPR as of Feb 29, 2024 were 16.95M with a Short Ratio of 2.82, compared to 20.07M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.16% and a Short% of Float of 10.23%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.46 and a low estimate of -$0.31, while EPS last year was -$0.79. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.25.
Analysts are recommending an EPS of between $0.04 and -$1 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is $0.2, with 5 analysts recommending between $1.49 and -$0.34.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $76.86M. It ranges from a high estimate of $141.69M to a low estimate of $28.9M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $24.33M, an estimated increase of 215.90% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $41.91M, an increase of 62.50% less than the figure of $215.90% in the same quarter last year. There is a high estimate of $48.35M for the next quarter, whereas the lowest estimate is $38M.
A total of 7 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $337.5M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $257.54M. In the same quarter a year ago, actual revenue was $116.33M, up 121.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $398.87M in the next fiscal year. The high estimate is $710.2M and the low estimate is $272.94M. The average revenue growth estimate for next year is up 54.90% from the average revenue estimate for this year.
